-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GSK-3494245 in Leishmaniasis (Kala-Azar)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GSK-3494245 in Leishmaniasis (Kala-Azar) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GSK-3494245 in Leishmaniasis (Kala-Azar) Drug Details: GSK-3494245 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – D-121 in Leishmaniasis (Kala-Azar)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - D-121 in Leishmaniasis (Kala-Azar) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. D-121 in Leishmaniasis (Kala-Azar) Drug Details: D-121 (Oleylphosphocholine) is under development...
-
Innovation Ranking
Innovation Ranking – Kala Pharmaceuticals Inc
Kala Pharmaceuticals Inc (Kala Pharmaceuticals) is a clinical stage pharmaceutical company. It offers nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. The company’s AMPPLIFY technology, treats the medical needs for the front of the eye, and NCEs, targeted to address front and back of the eye diseases. Its pipeline products includes EYSUVIS (loteprednol etabonate ophthalmic suspension), is used for the treatment of short-term (up to two weeks) treatment of the signs and symptoms of dry...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LXE-408 in Leishmaniasis (Kala-Azar)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LXE-408 in Leishmaniasis (Kala-Azar) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LXE-408 in Leishmaniasis (Kala-Azar) Drug Details: LXE-408 is under development for the...
-
Product Insights
NewLeishmaniasis (Kala-Azar) – Drugs In Development, 2024
Empower your strategies with our Leishmaniasis (Kala-Azar) – Drugs In Development, 2024 report and make more profitable business decisions. Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen, and fever. Treatment includes anti-parasitic drugs. The Leishmaniasis (Kala-Azar) drugs in development market research report provide comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete...
-
Product Insights
NewSuperoxide Dismutase – Drugs In Development, 2024
The Superoxide Dismutase pipeline drugs market research report outlays comprehensive information on the Superoxide Dismutase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Infectious Disease, and Toxicology which include indications of Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Leishmaniasis (Kala-Azar), Chagas Disease (American Trypanosomiasis), and Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). It also reviews key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DB-1303 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DB-1303 in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DB-1303 in Endometrial Cancer Drug Details: DB-1303 is under development for...
-
Product Insights
NewQuarterly Herbs, Spices & Seasonings pricing trends in Canada
Empower your strategies with our Quarterly Herbs, Spices & Seasonings pricing trends in Canada report and make more profitable business decisions. Consumers’ preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and implement...
-
Analyst Opinions
Mobile World Congress (MWC) 2024 – Startups Race for Digital Change
Mobile World Congress (MWC) 2024 Report Overview MWC (Mobile World Congress) is a premier global event for the mobile technology industry, while 4YFN (4 Years from Now) is its associated platform focusing on connecting startups with investors and partners to drive innovation. With over 40 companies in attendance, AI startups took center stage at MWC 2024, signaling robust investor and market interest in AI as the key driver for future innovation. Beyond AI, fintech, digitalization, IoT, digital media, and health...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KPI-012 in Persistent Corneal Epithelial Defects
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KPI-012 in Persistent Corneal Epithelial Defects report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KPI-012 in Persistent Corneal Epithelial Defects Drug Details: KPI-012...